We are live on
!
Find out more
PA
Perceptive Advisors Portfolio holdings
AUM
$6.66B
1-Year Est. Return
360.84%
This Fund
S&P 500
This Quarter
Est. Return
-16.07%
1 Year Est. Return
+360.84%
3 Year Est. Return
+1,707.27%
5 Year Est. Return
+3,210.42%
10 Year Est. Return
+53,055.89%
AUM
$1.14B
AUM Growth
-$212M
(-16%)
Cap. Flow
+$98.4M
Cap. Flow
% of AUM
8.63%
Top 10 Holdings %
Top 10 Hldgs %
46.56%
Holding
206
New
51
Increased
51
Reduced
18
Closed
36
Avg Time Held Equity + Options
3
quarters
Top 10 Avg Time Held Equity + Options
4.1
quarters
Top 20 Avg Time Held Equity + Options
4.2
quarters
Avg Time Held Equity only
3.1
quarters
Top 10 Avg Time Held Equity only
4.1
quarters
Top 20 Avg Time Held Equity only
4.3
quarters
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Sarepta Therapeutics
SRPT
|
+$27.8M |
| 2 |
Humana
HUM
|
+$19.1M |
| 3 |
XLRN
Acceleron Pharma
XLRN
|
+$15.3M |
| 4 |
QTNT
Quotient Limited Ordinary Shares
QTNT
|
+$13.2M |
| 5 |
MDVN
MEDIVATION, INC.
MDVN
|
+$12.3M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
DYAX
DYAX CORPORATION
DYAX
|
+$68.4M |
| 2 |
Teva Pharmaceutical Industries Limited
TEVA
|
+$12.9M |
| 3 |
Baxter International
BAX
|
+$10.1M |
| 4 |
BLCM
Bellicum Pharmaceuticals, Inc.
BLCM
|
+$8.54M |
| 5 |
NEVRO CORP.
NVRO
|
+$8M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 92.87% |
| 2 | Miscellaneous | 6.35% |
| 3 | Consumer Staples | 0.6% |
| 4 | Consumer Discretionary | 0.11% |
| 5 | Industrials | 0.04% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | Held Since | |
|---|---|---|---|---|---|---|---|
26
Sonida Senior Living
SNDA
$1.73B
| $10.1M | 0.88% |
36,309
+4,062
| +13% | +$1.06M |
2014 Q4
5 quarters
|
|
27
CytomX Therapeutics
CTMX
$508M
| $9.57M | 0.84% |
742,021
+99,974
| +16% | +$1.39M |
2015 Q4
1 quarter
|
|
|
PFNX
28
DELISTED
Pfenex Inc.
PFNX
| $9.45M | 0.83% |
960,877
| – | – |
2014 Q3
6 quarters
|
|
29
DELISTED
Cidara Therapeutics
CDTX
| $9.43M | 0.83% |
37,143
| – | – |
2015 Q2
3 quarters
|
|
|
ALDR
30
DELISTED
Alder Biopharmaceuticals
ALDR
| $9.18M | 0.81% |
+375,000
| New | +$8.68M |
2016 Q1
0 quarters
|
|
|
RXDX
31
DELISTED
Ignyta, Inc.
RXDX
| $9.12M | 0.8% |
1,347,060
-465,000
| -26% | -$3.83M |
2015 Q2
3 quarters
|
|
|
AGTC
32
DELISTED
Applied Genetic Technologies Corporation
AGTC
| $9.1M | 0.8% |
650,591
-210,922
| -24% | -$3.09M |
2014 Q2
7 quarters
|
|
33
DELISTED
Assertio
ASRT
| $9.05M | 0.79% |
10,833
+2,500
| +30% | +$2.32M |
2015 Q4
1 quarter
|
|
|
34
Baxter International
BAX
$12.9B
| $9.04M | 0.79% |
220,000
-265,000
| -55% | -$10.1M |
2015 Q3
2 quarters
|
|
35
Regenxbio
RGNX
$479M
| $8.91M | 0.78% |
825,396
+46,183
| +6% | +$591K |
2015 Q3
2 quarters
|
|
|
ZYNE
36
DELISTED
Zynerba Pharmaceuticals, Inc
ZYNE
| $8.03M | 0.7% |
849,350
+290,904
| +52% | +$2.35M |
2015 Q3
2 quarters
|
|
37
Akebia Therapeutics
AKBA
$213M
| $7.79M | 0.68% |
865,000
+605,000
| +233% | +$4.91M |
2015 Q3
2 quarters
|
|
38
DELISTED
VBI Vaccines, Inc. New Common Stock (Canada)
VBIV
| $7.66M | 0.67% |
108,679
| – | – |
2015 Q1
4 quarters
|
|
39
DELISTED
Eagle Pharmaceuticals, Inc.
EGRX
| $7.58M | 0.67% |
187,215
+54,070
| +41% | +$3.43M |
2015 Q1
4 quarters
|
|
40
Vericel Corp
VCEL
$2.06B
| $7.31M | 0.64% |
1,247,312
+941,650
| +308% | +$2.64M |
2014 Q3
6 quarters
|
|
41
DELISTED
Blueprint Medicines
BPMC
| $7.3M | 0.64% |
404,404
| – | – |
2015 Q2
3 quarters
|
|
|
42
CALL
Baxter International
BAX
$12.9B
| $7.17M | 0.63% |
175,400
+75,400
| +75% | +$2.87M |
2015 Q4
1 quarter
|
|
43
EyePoint Inc
EYPT
$265M
| $7.14M | 0.63% |
266,500
+225,000
| +542% | +$7.11M |
2014 Q4
5 quarters
|
|
44
Acadia Pharmaceuticals
ACAD
$3.21B
| $7.14M | 0.63% |
255,240
+10,000
| +4% | +$218K |
2014 Q1
8 quarters
|
|
|
NEPT
45
DELISTED
Neptune Wellness Solutions Inc. Ordinary Shares
NEPT
| $6.75M | 0.59% |
4,822
+36
| +0.8% | +$53.9K |
2013 Q2
11 quarters
|
|
46
Evolent Health
EVH
$520M
| $6.54M | 0.57% |
618,930
+471,330
| +319% | +$4.87M |
2015 Q2
3 quarters
|
|
47
Novo Nordisk
NVO
$168B
| $6.32M | 0.55% |
233,320
+214,240
| +1,123% | +$5.74M |
2015 Q2
3 quarters
|
|
|
MRTX
48
DELISTED
Mirati Therapeutics, Inc. Common Stock
MRTX
| $5.84M | 0.51% |
+273,000
| New | +$6.1M |
2016 Q1
0 quarters
|
|
|
HZNP
49
DELISTED
Horizon Therapeutics Public Limited Company Ordinary Shares
HZNP
| $5.8M | 0.51% |
+350,000
| New | +$6.12M |
2016 Q1
0 quarters
|
|
|
50
CALL
DELISTED
NEVRO CORP.
NVRO
| $5.63M | 0.49% |
+100,000
| New | +$5.9M |
2016 Q1
0 quarters
|
|
Similar funds
QP
FCBT
RWM
AWA
WHRC
KGA
LSERS
CAG
Perceptive Advisors's Q1 2016 Portfolio in Review
As of Q1 2016, Perceptive Advisors held 206 positions worth $1.14B, down 16% from $1.35B the previous quarter. Its ten largest holdings account for 47% of the portfolio.
Perceptive Advisors deployed $98.4M of net new capital in Q1 2016, opening 51 new positions and adding to 51 existing holdings. Its largest new stake was Humana: 110,000 shares worth $20.1M.
By sector, the portfolio is most concentrated in Healthcare at 93% of assets, up from 89% a quarter earlier, followed by Miscellaneous and Consumer Staples.
On the sell side, the largest reduction was Teva Pharmaceutical Industries Limited, an estimated $12.9M trimmed.
- Perceptive Advisors's largest Q1 2016 buy was Humana: 110,000 shares worth $20.1M.
- Perceptive Advisors added most to Sarepta Therapeutics in Q1 2016, an estimated $27.8M increase.
- Perceptive Advisors's biggest Q1 2016 reduction was Teva Pharmaceutical Industries Limited, cutting an estimated $12.9M.
- Perceptive Advisors fully exited DYAX CORPORATION in Q1 2016, selling an estimated $68.4M.
- Perceptive Advisors's ten largest holdings make up 47% of its $1.14B portfolio in Q1 2016.
- Perceptive Advisors opened 51 new positions and closed 36 in Q1 2016.
- Perceptive Advisors's portfolio value fell 16% quarter-over-quarter to $1.14B.
Based on Perceptive Advisors's 13F filing for Q1 2016, filed 16 May 2016.